Table 1 Baseline characteristics
Variables | Sorafenib arm (n = 588) | Sorafenib arm (n = 542) |
|---|---|---|
Brivanib trial | Sunitinib trial | |
Age (years) | 60 (12.19), n = 588 | 58 (12.94), n = 542 |
Sex (% male) | 492 (83.67), n = 588 | 457 (84.32), n = 542 |
Race (%) | n = 588 | n = 542 |
Asian | 396 (67.35) | 417 (76.94) |
Caucasian | 176 (29.93) | 111 (20.48) |
Black | 9 (1.53) | 10 (1.85) |
Other | 7 (1.19) | 4 (0.74) |
ECOG | n = 588 | n = 539 |
0 | 352 (59.86) | 289 (53.62) |
1 | 236 (40.14) | 250 (46.38) |
Child-Pugh grade | n = 575 | n = 542 |
A | 529 (92.00) | 542 (100.00) |
B | 46 (8.00) | 0 (0.00) |
C | 0 (0.00) | 0 (0.00) |
Aetiology | n = 588 | n = 532 |
HCV | 112 (19.05) | 106 (19.92) |
HBV | 254 (43.20) | 276 (51.88) |
Other | 222 (37.76) | 150 (28.20) |
Tumour type (% multifocal) | 424 (76.81), n = 552 | 353 (71.31), n = 495 |
Tumour number | 3 (2, 4), n = 522 | 2 (1, 4), n = 495 |
Tumour size group (%) | n = 552 | n = 542 |
< = 2 cm | 72 (13.04) | 84 (15.50) |
>2 and < = 3 cm | 69 (12.50) | 78 (14.39) |
>3 and < = 5 cm | 111 (20.11) | 92 (16.97) |
>5 and < = 7 cm | 78 (14.13) | 87 (16.05) |
>7 and < = 10 cm | 78 (14.13) | 91 (16.79) |
>10 cm | 144 (26.09) | 110 (20.30) |
Extra-hepatic spread (%) | 421 (71.60), n = 588 | 352 (64.94), n = 542 |
Vascular invasion (%) | 170 (28.91), n = 588 | 161 (30.55), n = 527 |
Creatinine (µmol/L) | 74.26 (64.09, 86.63), n = 588 | 75.07 (63.00, 88.40), n = 492 |
Bilirubin (µmol/L) | 13.68 (10.26, 20.52), n = 586 | 15.39 (10.43, 20.52), n = 489 |
AST (U/L) | 57 (35, 93), n = 581 | 56 (35, 87), n = 489 |
AFP (ng/ml) | 180.75 (8.50, 2984.30), n = 572 | 305.05 (13.00, 4000.00), n = 486 |
Albumin (g/l) | 39 (5.21), n = 580 | 39 (5.04), n = 492 |
INR | 1.09 (0.14), n = 557 | 1.08 (0.10), n = 469 |
Death (%) | 419 (71.26), n = 588 | 386 (77.98), n = 495 |
Overall survival range, months (within those who died) | 0.1 – 31.28, n = 419 | 0.4 – 31.35, n = 386 |
Median overall survival, months (95% CI) | 9.77 (8.49, 11.51), n = 588 | 8.91 (7.89, 10.20), n = 495 |
